In 2014, a steering committee of experts from a wide range of disciplines was established to update the 2010 DMD guidance. This guidance, published in March 2018 aims to address the needs of patients with prolonged survival, to provide guidance on advances in assessments and interventions, , and to consider the implications of emerging genetic and molecular therapies for DMD. Part 1 of the guidance presents care includes growth, puberty and adrenal insufficiency, nutrition and dysphagia management.
Birnkrant, D J. et al. 2018. Duchenne Muscular Dystrophy: Part 1 - diagnosis, neuromuscular, rehabilitation, endocrine, gastrointestinal and nutritional management. Lancet Neurology, March 17 (3) p 251-267.
Contact the Library for a copy